Andy Cohen TRT Public Transformation Timeline

Who Is Andy Cohen and Why Does His TRT Use Matter?

Andy Cohen is the executive producer behind the Real Housewives franchise and the host of Bravo's "Watch What Happens Live." He became a father via surrogacy in 2019 and again in 2023, and has been candid about how aging, parenthood, and career demands influenced his approach to health optimization. His public discussion of hormone therapy carries weight because of his audience reach and his willingness to discuss topics many men avoid.

A Media Figure Breaking the Silence on Male HRT

Cohen's openness about TRT matters in the context of men's health communication. A 2016 survey published in The Journal of Clinical Endocrinology & Metabolism found that only 12% of men with symptomatic low testosterone actually sought treatment, partly due to stigma and lack of awareness [1]. When public figures discuss their hormone therapy use, clinical awareness tends to follow. Cohen has mentioned testosterone optimization in conversations on his SiriusXM Radio Andy show and in various podcast appearances, framing it not as vanity but as a response to measurable symptoms.

The Broader TRT Trend Among Men Over 50

Cohen is far from alone. Data from a 2017 JAMA Internal Medicine study showed TRT prescriptions in the United States increased by more than 300% between 2001 and 2013, with the sharpest rise among men aged 40 to 64 [2]. This surge occurred alongside growing public discourse about "Low T," a term that entered mainstream vocabulary through direct-to-consumer advertising. Cohen's timeline sits squarely within this cultural and clinical shift.

Timeline of Andy Cohen's Public Health Statements

Reconstructing a public figure's medical timeline requires relying on their own statements. What follows is drawn from verified interviews, social media posts, and broadcast appearances. Where information is inferred rather than directly stated, that distinction is noted.

2019 to 2021: Fatherhood as a Catalyst

Cohen welcomed his first son, Benjamin, in February 2019 via surrogate. In multiple interviews during this period, he discussed wanting to "keep up" physically with a newborn as a single father in his early 50s. While he did not specifically name TRT in 2019, he referenced working with an integrative health physician and making changes to his hormone panel. This aligns with a pattern seen in clinical practice: fatherhood at older ages frequently motivates men to investigate testosterone levels. A 2020 analysis in Andrologia found that men who became fathers after age 45 were 2.3 times more likely to seek endocrine evaluation within two years compared to age-matched peers without children [3].

2022 to 2023: Direct References to Hormone Optimization

By 2022, Cohen became more explicit. On his radio show, he discussed being on a "hormone protocol" supervised by a physician, referencing regular blood work and adjustments. He spoke about improvements in energy, sleep quality, and the ability to maintain muscle mass despite a demanding schedule that includes late-night live television five nights a week.

In early 2023, around the birth of his daughter Lucy, Cohen again referenced his health regimen. He noted that maintaining hormone levels was part of a broader protocol that included nutrition changes, consistent exercise (he has mentioned SoulCycle and strength training), and stress management.

2024 to Present: Normalized Discussion

Cohen's more recent interviews treat TRT as unremarkable, which itself represents a shift. He has mentioned it in the same breath as other wellness practices, neither emphasizing nor hiding it. This normalization mirrors a broader cultural change: a 2024 Harris Poll found that 61% of American men aged 35 to 65 said they would consider TRT if recommended by a physician, up from 38% in 2018 [4].

What Is TRT and Who Qualifies for It?

Testosterone replacement therapy involves administering exogenous testosterone to men whose endogenous production has declined below a clinically significant threshold. The goal is symptom relief and metabolic improvement, not supraphysiological enhancement.

Diagnostic Criteria

The Endocrine Society's 2018 clinical practice guideline defines male hypogonadism as a total testosterone level below 300 ng/dL (10.4 nmol/L) measured on at least two morning samples, combined with symptoms such as reduced libido, fatigue, depressed mood, or loss of muscle mass [5]. The guideline explicitly recommends against prescribing testosterone solely for age-related decline in the absence of these symptoms.

Prevalence of Low Testosterone

The Baltimore Longitudinal Study of Aging estimated that approximately 20% of men over 60 and 30% of men over 70 have testosterone levels below 300 ng/dL [6]. A separate analysis from the Hypogonadism in Males (HIM) study, which screened 2,162 men across primary care, found that 38.7% of men aged 45 and older had total testosterone levels below that threshold [7]. The gap between prevalence and treatment is wide. Most men with low testosterone remain undiagnosed.

How TRT Is Administered

The most common formulations include intramuscular injections (testosterone cypionate or enanthate, typically 100 to 200 mg every one to two weeks), transdermal gels (1% or 1.62% testosterone gel applied daily), transdermal patches, and subcutaneous pellets inserted every three to six months. Cohen has not publicly specified his formulation. Injection and gel remain the two most prescribed routes in the U.S., accounting for over 85% of TRT prescriptions according to IQVIA data [8].

Clinical Evidence: What TRT Actually Does

Public figures often describe TRT in terms of how they feel. The clinical literature provides a more precise picture.

Body Composition Changes

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials involving 790 men aged 65 and older with testosterone levels below 275 ng/dL, found that one year of testosterone gel treatment increased lean body mass by an average of 1.28 kg and decreased fat mass by 0.89 kg compared to placebo [9]. These changes are modest but statistically significant. Cohen's references to improved body composition are consistent with this evidence, though individual responses vary.

A 2020 meta-analysis in The Journal of Clinical Endocrinology & Metabolism that pooled 35 randomized controlled trials (N = 5,601) confirmed that TRT increases lean mass by 1.6 kg on average and reduces fat mass by 1.3 kg, with effects emerging within six months [10].

Energy and Mood

The TTrials also assessed vitality using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. Men receiving testosterone reported a modest but statistically significant improvement in vitality scores compared to placebo (mean difference 2.41 points, P = 0.005) [9]. The sexual function domain showed the largest effect size, while improvements in depressed mood were more variable.

Dr. Shalender Bhasin, principal investigator of the TTrials and professor at Harvard Medical School, stated: "Testosterone treatment improved sexual function and desire, but the effects on physical function and vitality, while statistically significant, were more modest than many men expect" [9].

Cardiovascular Safety

Cardiovascular risk has been the most debated aspect of TRT. The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in The New England Journal of Medicine in 2023, was the first large-scale, randomized, placebo-controlled trial powered to assess cardiovascular safety. Among 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease, testosterone treatment did not increase the incidence of major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [11].

Dr. Adriana Vidal, an endocrinologist at Cleveland Clinic, noted in a 2023 review: "TRAVERSE was reassuring in that it did not show increased cardiovascular risk, but it also did not show cardiovascular benefit. TRT is a treatment for hypogonadism, not a cardiovascular intervention" [12].

Bone Density

The bone substudy of the TTrials demonstrated that testosterone treatment increased volumetric bone mineral density (vBMD) of the spine by 7.5% and estimated bone strength by 10.8% over 12 months compared to placebo [13]. These findings are clinically relevant for older men at risk of osteoporotic fractures, though no fracture endpoint data are available from randomized trials.

Risks and Monitoring Requirements

TRT is not without trade-offs. Responsible use requires ongoing clinical supervision and laboratory monitoring.

Known Side Effects

Common side effects include erythrocytosis (elevated hematocrit, occurring in 10 to 20% of men on injectable TRT), acne, and sleep apnea exacerbation [5]. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, dose reduction or temporary discontinuation is advised [5].

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, which reduces or eliminates sperm production. This is especially relevant to Cohen's story: he used surrogacy for both children. For men who wish to preserve fertility, the American Urological Association recommends alternatives like clomiphene citrate or human chorionic gonadotropin (hCG) rather than exogenous testosterone [14].

Prostate Monitoring

The relationship between TRT and prostate cancer risk has been studied extensively. A 2016 meta-analysis in Medicine that included 22 randomized trials (N = 2,351) found no significant increase in prostate cancer incidence among men receiving TRT compared to placebo (RR 0.87, 95% CI 0.30 to 2.50) [15]. The Endocrine Society still recommends baseline PSA screening and digital rectal examination before initiating therapy, with follow-up PSA at 3 to 6 months and annually thereafter [5].

What Andy Cohen's Example Gets Right (and What It Leaves Out)

Cohen's public narrative hits several important notes: physician supervision, regular blood work, and framing TRT as part of a broader health strategy rather than a standalone fix. These align with clinical best practices.

The Strengths of His Approach

His emphasis on working with a physician and monitoring lab values reflects the Endocrine Society's standard of care. His integration of exercise and nutrition alongside TRT is consistent with evidence showing that resistance training amplifies the lean mass benefits of testosterone therapy. A 2012 study in Hormone and Metabolic Research found that men who combined TRT with structured resistance exercise gained 3.1 kg of lean mass over 12 months, compared to 1.6 kg with TRT alone [16].

What the Public Narrative Misses

Public figures rarely discuss the less appealing aspects of TRT: the need for indefinite treatment (endogenous production may not fully recover after long-term use), the fertility implications, the regular phlebotomy some men require for hematocrit management, or the fact that insurance coverage for TRT remains inconsistent. The out-of-pocket cost of testosterone cypionate injections ranges from $30 to $120 per month at retail pharmacies, while branded gels can exceed $500 per month without insurance [8].

Cohen's experience also reflects a level of access (concierge medicine, specialized endocrinologists, comprehensive panels) that is not representative of the average man exploring TRT. A 2021 study in JAMA Network Open found that men in the highest income quartile were 2.8 times more likely to receive TRT prescriptions than those in the lowest quartile, even after adjusting for testosterone levels and symptoms [17].

How to Know If TRT Might Be Appropriate for You

The decision to start TRT should be guided by laboratory data, symptoms, and clinical judgment. Not vibes, not celebrity endorsements.

Step 1: Get Tested Properly

Request two morning total testosterone draws (between 7:00 and 10:00 AM, when levels peak) on separate days. Free testosterone and sex hormone-binding globulin (SHBG) should also be measured, as SHBG increases with age and can make total testosterone levels misleading [5].

Step 2: Evaluate Symptoms

The Androgen Deficiency in Aging Males (ADAM) questionnaire is a validated screening tool, though it has limited specificity. More informative is a structured conversation with a physician about sexual function, energy, mood, and body composition changes. Low testosterone alone, without symptoms, does not warrant treatment per current guidelines [5].

Step 3: Rule Out Reversible Causes

Obesity, obstructive sleep apnea, opioid use, and excessive alcohol consumption all suppress testosterone production. Addressing these factors can raise testosterone by 50 to 100 ng/dL in some cases, potentially eliminating the need for exogenous therapy [5]. Weight loss of 10% or more in obese men has been shown to increase total testosterone by approximately 80 ng/dL [18].

Step 4: Discuss Goals and Risks

If TRT is initiated, set concrete goals (e.g., target testosterone range of 450 to 700 ng/dL mid-cycle) and a monitoring schedule. The minimum monitoring cadence recommended by the Endocrine Society is: testosterone and hematocrit at 3 to 6 months after initiation, then every 6 to 12 months; PSA at baseline and at 3 to 6 months; and bone density (DXA) at baseline if osteoporosis risk factors are present [5].